Yondelis to be filed for ovarian cancer after Phase III success
This article was originally published in Scrip
PharmaMar's anticancer Yondelis (trabectedin) has succeeded in extending progression-free survival (PFS) in its pivotal Phase III trial in relapsed ovarian cancer, and the Spanish company and its US partner Ortho Biotech (Johnson & Johnson) will seek both EU and US approval before the end of the year for this important indication.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.